The company has not filed an annual or quarterly report since its Q2 FY2020 10-Q, filed Aug 7, 2020. Its latest SEC filing is a SC 13G/A from Feb 10, 2021.
10-Q for Q2 FY2020, filed Aug 7, 2020
The sections below describe the company as of the FY2019 annual report.
Developed, manufactured and marketed generic and branded prescription medicines, consumer health products and animal medicines for drug wholesalers, hospitals and veterinary professionals.
10-K for FY2019, filed Feb 26, 2020Akorn, Inc., together with its wholly-owned subsidiaries (“Akorn,” the “Company,” “we,” “our” or “us”) is a specialty pharmaceutical…View ↗
Targeted sales and marketing infrastructure. We maintain a targeted sales and marketing infrastructure to promote our branded, generic, OTC…View ↗
Consumer Health Segment. Our Consumer Health segment primarily consists of branded and private-label OTC products and animal health…View ↗
Our field sales representatives promote ophthalmic products directly to glaucoma specialists, retinal surgeons and ophthalmologists, and…View ↗
Customers paid for products upon delivery; payment terms were primarily less than 90 days.
10-K for FY2019, filed Feb 26, 2020Revenue Recognition: Revenue is recognized at a point in time upon the transfer of control of the Company’s products, which occurs upon…View ↗
$682.4M
10-K for FY2019, filed Feb 27, 2020
$682.4M ↗
Wholesalers distributed prescription products; sales representatives promoted ophthalmic products directly to specialists and other pharmaceuticals directly to hospitals. Chain pharmacies were major Consumer Health customers.
10-K for FY2019, filed Feb 26, 2020Our field sales representatives promote ophthalmic products directly to glaucoma specialists, retinal surgeons and ophthalmologists, and…View ↗
Amerisource, Cardinal and McKesson are key distributors of our products, as well as a broad range of healthcare products for many other…View ↗
Sales to the Big 3 Wholesalers primarily represent purchases of products in the Prescription Pharmaceuticals segment and generate the…View ↗
No. It lost $226.8M in FY2019.
10-K for FY2019, filed Feb 27, 2020
−$188.1MView ↗
10-K for FY2019, filed Feb 27, 2020
−$226.8MView ↗
10-K for FY2019, filed Feb 27, 2020
−$67.4MView ↗
10-Q for Q2 FY2020, filed Aug 8, 2020
−$68.7MView ↗
8-K, filed Oct 2, 2020
The Company Parties entered into an asset purchase agreement (the “Stalking Horse APA”), dated as of May 20, 2020, with certain of the…View ↗
Shrank. Revenue fell 31% in 4 years, from $985.1M in FY2015 to $682.4M in FY2019, about 9% a year.
Competes with Teva Pharmaceutical Industries, Apotex, Fresenius Kabi, Hikma Pharmaceuticals, Novartis International, Alcon, Perrigo, Pfizer, Mylan, Amneal Pharmaceuticals, Taro Pharmaceutical Industries, Allergan, and Johnson & Johnson
10-K for FY2019, filed Feb 26, 2020Generic Pharmaceuticals. Companies that compete with our generic pharmaceuticals portfolio include Teva Pharmaceutical Industries Ltd.…View ↗
Loading...
